Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v15-EN | Version v9-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2025-11-29 | 2025-09-10 |
| Drug Identification Number | 02312557 | 02312557 |
| Brand name | BOOSTRIX-POLIO | BOOSTRIX-POLIO |
| Common or Proper name | Combined diphtheria, tetanus, acellular pertussis (adsorbed) and inactivated poliomyelitis vaccine | Combined diphtheria, tetanus, acellular pertussis (adsorbed) and inactivated poliomyelitis vaccine |
| Company Name | GLAXOSMITHKLINE INC | GLAXOSMITHKLINE INC |
| Ingredients | INACTIVATED POLIOVIRUS TYPE I PERTUSSIS TOXOID ADSORBED INACTIVATED POLIOVIRUS TYPE III INACTIVATED POLIOVIRUS TYPE II FILAMENTOUS HAEMAGGLUTININ ADSORBED TETANUS TOXOID ADSORBED PERTACTIN ADSORBED DIPHTHERIA TOXOID ADSORBED | INACTIVATED POLIOVIRUS TYPE I PERTUSSIS TOXOID ADSORBED INACTIVATED POLIOVIRUS TYPE III INACTIVATED POLIOVIRUS TYPE II FILAMENTOUS HAEMAGGLUTININ ADSORBED TETANUS TOXOID ADSORBED PERTACTIN ADSORBED DIPHTHERIA TOXOID ADSORBED |
| Strength(s) | 40D 8MCG 32D 8D 8MCG 5.0LF 2.5MCG 2.5LF | 40D 8MCG 32D 8D 8MCG 5.0LF 2.5MCG 2.5LF |
| Dosage form(s) | SUSPENSION | SUSPENSION |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | 10's | 10's |
| ATC code | J07CA | J07CA |
| ATC description | BACTERIAL AND VIRAL VACCINES, COMBINED | BACTERIAL AND VIRAL VACCINES, COMBINED |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2025-08-13 | 2025-08-13 |
| Estimated end date | 2025-11-30 | 2025-11-30 |
| Actual end date | 2025-11-28 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Current shortage impacts private market. Potential for future disruption in public programs. | Current shortage impacts private market. Potential for future disruption in public programs. |
| Health Canada comments |